Company research
DAXOR CORP
CIK 27367Updated Nov 13, 2026
SecurityDXR · NASDAQ · equity
DXR price & chart
Loading TradingView…
NASDAQ:DXR on TradingView ↗In the news
Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions ↗
Recent filings
Show 5 more recent filings
Financials
FY 2011 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2011 | Q3 2010 | Q2 2011 | Q2 2010 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| AssetsUSD | 88,252,642Source | — | 96,237,008Source | — | 85,724,861Source | 91,195,415Source |
| Property, Plant and Equipment, NetUSD | 4,065,934Source | — | 4,080,205Source | — | 4,001,351Source | 4,168,992Source |
| Current assets: | ||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 29,711Source | 107,043Source | 111,769Source | 213,402Source | 59,625Source | 57,741Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 189,612Source | — | 193,473Source | — | 219,684Source | 178,820Source |
| Inventory, NetUSD | 313,494Source | — | 357,334Source | — | 301,534Source | 363,634Source |
| Assets, CurrentUSD | 84,149,550Source | — | 92,119,645Source | — | 81,686,352Source | 86,989,265Source |
| Prepaid Expense and Other Assets, CurrentUSD | 338,333Source | — | 184,342Source | — | 209,339Source | 130,560Source |
| Other Assets, NoncurrentUSD | 37,158Source | — | 37,158Source | — | 37,158Source | 37,158Source |
| LIABILITIES AND EQUITY | ||||||
| LiabilitiesUSD | 50,630,590Source | — | 50,656,255Source | — | 49,508,270Source | 44,200,371Source |
| Stockholders’ equity: | ||||||
| Common Stock, Value, IssuedUSD | 53,165Source | — | 53,165Source | — | 53,165Source | 53,165Source |
| Additional Paid in CapitalUSD | 10,680,860Source | — | 10,677,074Source | — | 10,684,752Source | 10,675,228Source |
| Retained Earnings (Accumulated Deficit)USD | 26,651,971Source | — | 30,835,640Source | — | 24,740,252Source | 32,980,341Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 11,931,796Source | — | 15,641,808Source | — | 12,572,514Source | 14,890,272Source |
| Stockholders' Equity Attributable to ParentUSD | 37,622,052Source | — | 45,580,753Source | — | 36,216,591Source | 46,995,044Source |
| Liabilities and EquityUSD | 88,252,642Source | — | 96,237,008Source | — | 85,724,861Source | 91,195,415Source |
| Current liabilities: | ||||||
| Liabilities, CurrentUSD | 50,371,788Source | — | 50,382,856Source | — | 49,264,316Source | 43,900,308Source |
cash flow · annual statements
| Line item | Q4 2011 | Q4 2010 | Q3 2011 | Q3 2010 | Q2 2011 | Q2 2010 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 9,731Source | — |
| Changes in operating assets and liabilities: | ||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -45,864Source | 28,814Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 62,100Source | 90,773Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 1,249,624Source | 606,363Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -6,508,648Source | -5,690,083Source |
| Cash flows from investing activities: | ||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -11,388,438Source | 9,401,925Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 123,150Source | 324,710Source |
| Cash flows from financing activities: | ||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 17,898,970Source | -3,931,189Source |
| Dividends paid | — | — | — | — | — | — | —Source | —Source |
| Supplemental disclosure of cash flow information: | ||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 3,002,828Source | 2,424,813Source |
| Additional Financial Items | ||||||||
| DepreciationUSD | — | — | — | — | — | — | 290,791Source | 296,554Source |
| Income Tax Expense (Benefit)USD | — | — | -2,845,136Source | 1,799,112Source | -182,331Source | -39,946Source | -5,142,076Source | 3,381,892Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | -2,317,758Source | -1,126,103Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,183,669Source | 2,604,804Source | -184,520Source | 188,356Source | -7,185,639Source | 4,968,264Source |
| Nonoperating Income (Expense)USD | — | — | -5,767,733Source | 5,688,781Source | 976,946Source | 1,653,480Source | -6,541,301Source | 14,009,267Source |
| Operating ExpensesUSD | — | — | 1,452,603Source | 1,552,404Source | 1,541,209Source | 1,707,991Source | 6,580,248Source | 6,510,718Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | -168,923Source | -61,676Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 25,722,529Source | 28,856,997Source |
| Unrealized Gain (Loss) on DerivativesUSD | — | — | -6,608,910Source | 2,735,102Source | -1,687,134Source | -318,123Source | -8,501,859Source | -1,526,064Source |
| Payments for Repurchase of Common Stock | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2011 | Q4 2010 | Q3 2011 | Q3 2010 | Q2 2011 | Q2 2010 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 340,907Source | 453,281Source | 358,139Source | 368,332Source | 1,446,345Source | 1,579,257Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Selling, General and Administrative ExpenseUSD | — | — | 815,552Source | 857,674Source | 871,426Source | 973,422Source | 3,874,296Source | 3,469,078Source |
| Operating Income (Loss)USD | — | — | -1,261,072Source | -1,284,865Source | -1,343,797Source | -1,505,070Source | -5,786,414Source | -5,659,111Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | -168,923Source | -61,676Source |
| Income Tax Expense (Benefit)USD | — | — | -2,845,136Source | 1,799,112Source | -182,331Source | -39,946Source | -5,142,076Source | 3,381,892Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,183,669Source | 2,604,804Source | -184,520Source | 188,356Source | -7,185,639Source | 4,968,264Source |
| Additional Financial Items | ||||||||
| Cost of Goods Sold (Deprecated 2018-01-31)USD | — | — | 136,166Source | 174,014Source | 155,056Source | 156,329Source | 616,063Source | 691,786Source |
| Gross ProfitUSD | — | — | 191,531Source | 267,539Source | 197,412Source | 202,921Source | 793,834Source | 851,607Source |
| Nonoperating Income (Expense)USD | — | — | -5,767,733Source | 5,688,781Source | 976,946Source | 1,653,480Source | -6,541,301Source | 14,009,267Source |
| Operating ExpensesUSD | — | — | 1,452,603Source | 1,552,404Source | 1,541,209Source | 1,707,991Source | 6,580,248Source | 6,510,718Source |
| Other IncomeUSD | — | — | 3,093Source | 3,041Source | 3,094Source | 3,042Source | 12,374Source | 12,166Source |
| Research and Development ExpenseUSD | — | — | 637,051Source | 694,730Source | 669,783Source | 734,569Source | 2,705,952Source | 3,041,640Source |
| Weighted Average Number of Shares Outstanding, Basic | — | — | —Source | —Source | —Source | —Source | — | — |
| Interest Expense | — | — | —Source | —Source | —Source | —Source | — | — |
Offerings
Registration 333-281622
- Gross proceeds
- 9000006.0
- Net proceeds
- 8280006.0
- Deal price
- 11.75
- Shares
- 765958
- Offering amount
- $13.70
- Offering price
- $11.75
- Ticker
- DXR
Filing attachments
ex99-1.htm · 8-K · 2025-08-07
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System Management Expects High Demand Driven by Speed, Simplicity, and Clinical Precision Oak Ridge, TN - August 7, 2025 - Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces FDA 510(k) clearance (K251087) for its patent-pending next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer (…
Read attachment ↗